WO2007106389A2 - A method for stenting a vessel of a rodent and for facilitating monitoring of the effect of stenting a vessel of a rodent - Google Patents
A method for stenting a vessel of a rodent and for facilitating monitoring of the effect of stenting a vessel of a rodent Download PDFInfo
- Publication number
- WO2007106389A2 WO2007106389A2 PCT/US2007/006053 US2007006053W WO2007106389A2 WO 2007106389 A2 WO2007106389 A2 WO 2007106389A2 US 2007006053 W US2007006053 W US 2007006053W WO 2007106389 A2 WO2007106389 A2 WO 2007106389A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rodent
- vessel
- stent
- mouse
- donor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
- A61F2240/008—Means for testing implantable prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0081—Prosthesis for animals
Definitions
- This invention relates generally to implantable stents, such as in an arterial blood vessel.
- a stent In the year 2000 over 1 million patients underwent percutaneous coronary intervention (PCI), with almost half including the placement of an intra-coronary stent.
- PCI percutaneous coronary intervention
- a stent is a cylindrical device which serves to maintain the lumen within a blood vessel.
- stents are made of stainless steel.
- the stent is delivered to the target blood vessel, often an arterial blood vessel, via an expandable balloon catheter.
- Coronary artery disease manifests itself as symptoms such as chest pain and breathlessness due to a mismatch in oxygen supply and demand to the heart muscle.
- PCl is a well recognised treatment for stable coronary artery disease as well as unstable disease and evolving myocardial infarction.
- PCI has been limited by re-stenosis, occurring in 30% to 60% of patients receiving balloon angioplasty, and 20% to 40% of patients who in conjunction with balloon angioplasty also had an intra-coronary stent inserted.
- In-stent re-stenosis leads to recurrence of symptoms such as breathlessness or chest pain.
- In-stent stenosis is the result of the body's natural healing process as a result of injury to the vessel wall from the metallic stent struts and from the expansion of the balloon to high pressures, which is used to expand the stent strut within the blood vessel. Numerous methods have been attempted to reduce in-stent stenosis.
- stents may be coated with therapeutic agents by suspension from the surface of the stent strut from polymers such as silicones, polyurethanes, polyvinyl alcohol, poly(ethylene-co-vinyl alcohol), polyethylene, poly(lactide-co-caprolactone), hydrogels, substituted methacrylates, poly(ethylene-co-vinyl acetate), and hyaluronic acid.
- therapeutic agents include biocompatibles, antithrombotics, anticoagulants, steroids, antiinflammatory agents, cytostatic agents, cytotoxic agents, thrombolytics, monoclonal antibodies, and antifibrosis agents.
- vascular smooth muscle cells target proliferation of smooth muscle cells. Although highly successful, there is uncertainty over the potential harm these drugs may have in the long term on the natural vessel wall healing. Importantly, there are several other biological pathways which may be investigated as novel molecular targets for limiting re-stenosis. Experimental evidence from animals such as pig, canine and rabbit indicate that a number of biological factors are involved in the response to stent injury. Vascular injury by balloon angioplasty and the stent struts lead to disruption and loss of the endothelium, platelet aggregation and an acute inflammatory response. These cells release growth factors which activate vascular smooth muscle cells (VSMC).
- VSMC vascular smooth muscle cells
- mice the most widely used animals in vascular research.
- mice offer a number of advantages over larger animals.
- the entire mouse genome has been sequenced, allowing targeted deletion or up-regulation of specific genes.
- Established models of disease, such as atherosclerosis, are now available, as is the ability to track cells.
- genetically modified mice which have reporter genes that are expressed specifically by the endothelium (vessel wall lining) or smooth muscle cells may be easily identified using a simple staining procedure.
- mice are easy to handle and breed, whilst also cost effective.
- Atherosclerosis Genetically modified mice are available with a targeted deletion of the apolipoprotein-E gene, a key regulator of cholesterol metabolism. Such genetically modified mice are generally referred to as ApoE-KO mice. Wild type mice have very low cholesterol levels and are particularly resistant to the atherosclerosis. However, on standard rodent diet ApoE-KO mice have a total cholesterol >10mmol/l_, which increases to more than 25mmol/L with a high fat diet. Thus, these mice are prone to the development of typical atherosclerotic lesions in weeks rather than months required by larger animal models. Validated reproducible measurements of atherosclerosis may be taken from the aortic sinus, braciocephalic artery and descending thoracic aorta.
- Methods are provided for the insertion of a stent in a blood vessel of a rodent, e.g. mouse, rat, etc., particularly a mouse.
- the method comprises inserting a vascular stent into a rodent blood vessel; and transplanting the stented rodent blood vessel into a recipient rodent, thereby constructing a functional interposition graft.
- functional graft it is understood that the graft allows the flow of blood through the lumen of the vessel.
- the stented rodent is useful in a variety of analytic tests and assays relating to the effects of balloon angioplasty and stenting, stent design and materials, elution of biologically active agents from stents, local and systemic treatments and the like.
- the invention is further directed towards a rodent having a stent inserted in a vessel thereof.
- a stent suitable for insertion into rodent vasculature is provided.
- Methods for inserting a stent in a vessel of a rodent comprise installing a stent in a first vessel of a donor rodent, and grafting the stented first vessel from the donor rodent into a second vessel of a recipient rodent, which is optionally immunologically compatible, although in some embodiments the donor and recipient are immunologically mismatched.
- the stent is installed in the first vessel prior to removal from the donor rodent, while in an alternative embodiment of the invention the first vessel is removed from the donor rodent prior to the stent being installed therein.
- the second vessel is severed to produce two adjacent severed ends adjacent the severing, between which the stented first vessel is located, and the stented first vessel is grafted onto the respective severed ends of the second vessel.
- the second vessel may be clamped at two spaced apart locations on respective opposite sides of the site at which the second vessel is to be severed prior to severing of the second vessel, and advantageously, the second vessel remains clamped at the respective two spaced apart locations until the stented first vessel has been grafted into the second vessel.
- each severed end of the second vessel is passed through a central bore of a corresponding collar, and the respective portions adjacent the severed ends are folded back to embrace an outer periphery of the corresponding collars to form respective plug ends, and preferably, the portion adjacent each severed end embracing the outer periphery of the corresponding collar is secured thereto, and preferably, is secured by a first ligature extending around the portion adjacent the severed end and tied for securing the portion adjacent the severed end to the outer periphery of the collar.
- each plug end of the second vessel is secured in the corresponding end of the stented first vessel by a second ligature extending around the corresponding end of the stented first end adjacent the plug end and tied thereto for securing the corresponding end of the stented first vessel to the corresponding plug end of the second vessel.
- each collar is provided with a tab extending in a generally axial direction from one side thereof, and the corresponding portion of the second vessel adjacent the severed end is secured to the collar to form the plug end with the tab extending outwardly from the plug end intermediate the portion adjacent the severed end and a portion of the second vessel extending into the central bore of the collar so that the tab can be gripped by a gripping implement during insertion of the plug end of the second vessel into the corresponding end of the stented first vessel.
- the stent is installed in the first vessel intermediate the ends thereof, and preferably, spaced apart from the ends thereof, so that respective portions of the first vessel adjacent the ends thereof form respective sockets for receiving the corresponding plug ends of the second vessel creating a functional interposition graft, as known in the art, allowing flow of blood through lumen of the second vessel into the first vessel and back into the second vessel.
- the first vessel is secured to the second vessel creating a functional interposition graft by securing the first vessel to the collar and subsequently securing the second vessel to the first vessel, which is already secured to the collar using ligatures.
- the ligatures are replaced by adhesive glue or sutures.
- the first vessel is secured to the second vessel directly by the use of adhesive glue or sutures.
- the first vessel is provided by the thoracic aorta from the donor rodent, and preferably, the second vessel is provided by one of the carotid arteries of the recipient rodent.
- the stented first vessel is grafted into the carotid artery, and preferably, the common carotid artery.
- the stented first vessel is grafted into the carotid artery intermediate the thoracic inlet and the bifurcation portion thereof.
- the invention also provides a method for monitoring the effect of stenting in a vessel of a rodent, the method comprising installing a stent in a first vessel of a donor rodent, and grafting the stented first vessel from the donor rodent into a second vessel of a recipient rodent, so that the effect of stenting can be monitored.
- a stent is provided, which stent is suitable for use with a mouse blood vessel.
- the term stent is used as is known in the art, to refer to a prosthesis which can be inserted and held, when desired, in a lumen of a vessel or organ in the body.
- Materials commonly used in stent construction include biologically compatible metals, e.g. stainless steel, titanium, tantalum, gold, platinum, copper and the like, as well as alloys of these metals; low shape memory plastic; a shape- memory plastic or alloy, such as nitinol; and the like.
- a stent of the invention is at least about 1.5 mm in length, usually at least about 2.5 mm in length, and not more than about 5 mm in length, and may be around about 3 mm in length.
- the stent has a diameter prior to expanding of at least about 0.2 mm, usually around about 0.5 mm; and after expansion has a diameter of at least about 0.5 mm, usually at least about 1.0 mm, and not more than about 1.5 mm, usually not more than about 1.3 mm.
- the stent is optionally crimped onto a balloon of length of the order of about 5 to about 10 mm, and having a diameter after inflating of at least about 0.5 mm and not more than about 1.25mm.
- the balloon may be inflated to a pressure of about 8 atmospheres, for expanding the stent to its expanded diameter.
- the balloon may be inflated to about 8 atmospheres for expanding the stent for a period in the order of 10 seconds.
- the stent is coated with a medium, which may be a medium for minimising stenosis, or for delivery into the bloodstream or other stream passing through the vessel.
- a polymer such as ethylene vinyl alcohol copolymer (EVOH); polyb ⁇ tylmethacrylate; poly(hydroxyvalerate); poly(L-lactic acid); polycaprolactone; poly(lactide-co-caprolactone); poly(lactide-co-glycolide); poly(hydroxybutyrate); poly(hydroxybutyrate-co-valerate); polydioxanone; polyorthoester; polyanhydride; poly(glycolic acid); poly(D,L-lactic acid); poly(glycoiic acid-co-trimethylene carbonate); polyphosphoester; polyphosphoester urethane; poly(amino acids); cyanoacrylates; poly(trimethylene carbonate); poly(iminocarbonate); copoly(ether-
- EVOH ethylene vinyl alcohol copolymer
- the stent is a drug eluting stent.
- the stent is a drug coated stent.
- a biologically active agent is administered locally or systemically in conjunction with the stent or angioplasty process.
- drugs include, but are not limited to; antiproliferative, antineoplastic, antimitotic, antibiotic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antiallergic and antioxidant substances.
- Antiproliferative substances include, but are not limited to, substances such as actinomycin D, trichostatin, retinoic acid or derivatives/analogs thereof (Sigma-Aldrich, Milwaukee).
- Antineoplastic or antimitotic substances include, but are not limited to, paclitaxel (TAXOL.RTM, Bristol-Myers Squibb Co., Stamford, Conn.), docetaxel (Taxotere.RTM., Aventis S.
- Antiplatelet, anticoagulant, antifibrin, and antithrombin substances include, but are not limited to sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone, dipyridamole, glycoprotein llb/llla platelet membrane receptor antagonists, recombinant hirudin, and thrombin inhibitors such as Angiomax (Biogen, Inc., Cambridge, Mass.).
- Antiallergic substances include, but are not limited to, histamine antagonists, corticosteroids, cromoglicate sodium.
- Anti-inflammatory substances include, but are not limited to, corticosteroids, Non-steroidal anti-inflammatory drugs, Aspirin, Nuclear Factor Kappa B decoy, anti-chemokine agents, anti-tumor necrosis factor antibody, interleukin receptor antagonists and permirolast potassium.
- Agents which promote vascular healing and re- endothelialization include, but are not limited to, granulocyte macrophage colony-stimulating factor (GM-CSF), erythropoietin, estrogen, tetrahydrobiopterin, HMG-CoA reductase inhibitors, vascular endothelial growth factor, nitric oxide and nitric oxide donors to include, but are not limited to, Diethylamine NONOates, sodium nitroprusside, organic nitrates, S- nitroso-D,L-penicillaminamides, S-nitrosylated proteins or other S-nitrosothiols, hydroxynitrosohydrazino derivates, modified drugs with nitric oxide donor activity such as NO-aspirin (NO-ASA, NCX-4016) other COX-inhibiting nitric oxide donators (CINODs) or nitric oxide-generating enzyme systems, cofactors or substrates.
- Antioxidant substances include, but are not limited to, methytetrahydrofolate, ascorbic acid, glutathione, sulphur, lipoic acid, uric acid, carotenes, alpha-tocopherol and ubiquinone.
- Other substances include, but are not limited to, angiopeptin, angiotensin converting enzyme inhibitors such as captopril (Capoten. RTM.
- biologically active agents include, but are not limited to, antibodies, chimeric proteins or decoy inhibitors, genetic material delivered by agents such as viral gene transfer vectors or non-viral transfection methods, oligonucleotides or small interfering RNA molecules.
- agents such as viral gene transfer vectors or non-viral transfection methods, oligonucleotides or small interfering RNA molecules.
- the foregoing substances are listed by way of example and are not meant to be limiting. Other therapeutic substances which are currently available or that may be developed in the future are equally applicable.
- the recipient rodent is genetically modified, which genetic modification includes, without limitation, targeted deletion or upregulation of a gene, which gene may be involved in one or more cardiovascular pathways or pathologies.
- the modification may be conditional or constitutive, in either all cell types or in selected cell or tissue types.
- Genes of interest include, without limitation, the apolipoprotein-E gene, LDL receptor, angiotensin receptor, eNOS, iNOS, nNOS, and chemokines. For example, see Carmeliet and Collen (2000) J.
- the recipient rodent is optionally genetically modified with targeted transgenic overexpression of a reporter gene, including, without limitation, LacZ, GFP, luc, etc.
- the recipient animal is a cell lineage specific knockout (Cre-Lox).
- the recipient animal genetic modification is inducible and is time and cell specific (eg. tetracycline inducible).
- one or both of the donor and recipient rodents may be wild-type rodents.
- the donor rodent is a mouse, and in another embodiment of the invention the recipient rodent is a mouse.
- the recipient rodent and the donor rodent may be similarly genetically modified.
- the recipient rodent and the donor rodent may be differently genetically modified.
- a wild type donor stented vessel may be implanted into a LacZ, GFP, or luc expressing reporter recipient mouse.
- LacZ, GFP, or luc expressing reporter donor mouse stented vessel may be implanted into a wild type recipient mouse.
- an inducible stented vessel may be implanted into a LacZ, GFP, or luc expressing reporter recipient mouse and induced at various time points or vice versa.
- a specific cell lineage could be flanked by lox p sites in the stented vessel and be implanted into a cre-recombinase expressing recipient mouse or vice versa.
- Genetic manipulations have been used in mouse models of cardiovascular disease for cell tracking.
- Genetically modified mice are available with a targeted insertion of reporter genes that can be used to identify specific cell types.
- Examples of such genetically modified mice include, but are not limited to, beta-galactosidase (LacZ), green fluorescence protein (GFP) or luciferase (luc) strains.
- Specific cell types including, without limitation, expression in one or more endothelial cell types, such as the Tie2 gene and/or promoter, expression in one or more smooth muscle cell types, such as the SM22 gene and/or promoter; expression in various cells involved in inflammation, e.g. macrophages, monocytes, lymphocytes, dendritic cells, etc.; and the like. Markers can be readily identified using staining procedures or imaging modalities such as fluorescence microscopy or bioluminescence. Validated reproducible measurements of cell composition may be therefore taken.
- either the recipient or donor animal receives transplanted bone marrow, bone-marrow derived cells, or other progenitor cells or stem cells either prior to or after the angioplasty or stent procedure.
- the transplanted or transferred cells may be derived from wild type or genetically modified animals, or may undergo prior treatment with drugs or gene delivery techniques and may be administered systemically or locally.
- the invention also provides a method for monitoring of the effect of a procedure, device, genetic modification, or biologically active agent on a vessel of a rodent, the method comprising carrying out the procedure on a first vessel of a donor rodent, and grafting the first vessel having been subjected to the procedure from the donor rodent into a second vessel of a recipient rodent, so that the effect of the procedure can be monitored.
- the procedure is carried out in the first vessel prior to removal from the donor rodent, while in an alternative embodiment of the invention the first vessel is removed from the donor rodent prior to the procedure being carried out on the first vessel.
- Procedures of interest include, without limitation, balloon angioplasty, installation of a stent, etc. which may be conducted in the presence or absence of biologically active agents, e.g. local or systemic pre-treatment of the animal with a drug of interest; local or systemic administration of a drug of interest following balloon angioplasty, and the like.
- biologically active agents e.g. local or systemic pre-treatment of the animal with a drug of interest; local or systemic administration of a drug of interest following balloon angioplasty, and the like.
- the invention further provides a method for testing the results of a procedure carried out on a vessel of a rodent, whereby a procedure is carried out on a first vessel of a donor rodent, and grafted into a second vessel of a recipient rodent according to the method of the invention for carrying out a procedure in a vessel of a rodent, the test method comprising removing the first vessel on which the procedure was carried out from the recipient rodent after a predetermined test time period, ranging from brief intervals immediately postprocedure to long term effects observable months to years after the stenting procedure, for investigating the effect of the procedure on the first vessel.
- Methods of assessment include, without limitation, histology, immunohistochemistry, angiography, computed tomography, intravascular ultrasound, optical coherence tomography, optical bioilluminescence, ultrasonography, doppler ultrasonography, magnetic resonance imaging, immunoblotting, real-time polymerase chain reaction, proteomic or metabolomic analysis, transcriptional and genomic analysis by microrarray or other high- throughput technology, fluorescence activated cell sorting, etc.
- the preparation of the second vessel of the recipient rodent prior to grafting the first vessel from the donor vessel into the second vessel is similar to the preparation of the second vessel of the recipient rodent already described for grafting the stented first vessel into the second vessel of the recipient rodent.
- the invention also provides a method for testing stenting in a vessel of a rodent whereby a stent is installed in a first vessel of a donor rodent and grafted into a second vessel of a recipient rodent according to the method according to the invention for inserting a stent in a vessel of a rodent, the test method comprising removing the stented first vessel from the recipient rodent after a predetermined test period for investigating the effect of stenting of the first vessel.
- the invention also provides a recipient rodent having a stented first vessel grafted into a second vessel of the recipient rodent, and preferably, the stented first vessel is grafted into a carotid artery of the recipient rodent, and ideally, the stented first vessel comprises a portion of a thoracic aorta removed from a donor rodent, which preferably, is stented prior to being removed from the donor rodent.
- the invention also provides a recipient rodent having a first vessel on which a procedure was carried out grafted into a second vessel of the recipient rodent, and preferably, the first vessel is obtained from a donor rodent; and the procedure is carried out in one embodiment of the invention prior to removal of the first vessel from the donor rodent, and in an alternative embodiment of the invention the procedure is carried out subsequent to removal of the vessel from the donor rodent.
- the first vessel is grafted into a carotid artery of the recipient rodent, and ideally, the first vessel comprises a thoracic aorta of the donor rodent.
- the procedure is a balloon angioplasty, and in another embodiment of the invention the procedure comprises the installation of a stent in the first vessel.
- Fig. 1 is a partly cutaway perspective view of a second vessel of a recipient rodent into which a first stented vessel from a donor rodent has been grafted by a method according to the invention for inserting a stent in a vessel of a rodent,
- Fig. 2 is a perspective view of a portion of the second vessel of the recipient rodent of Fig. 1 during the carrying out of the method according to the invention
- Fig. 3 is a partly cutaway perspective view of the first stented vessel of Fig. 1 ,
- Fig. 4 is a partly cutaway perspective view of the first vessel of Fig. 1 with a stent being inserted therein,
- Fig. 5 is a perspective view of a collar used in the method according to the invention for inserting a stent in a rodent
- Fig. 6 is a perspective view of a portion of the second vessel of Fig. 1 being engaged in the collar of Fig. 5.
- Fig. 7 is a perspective view of the stent apparatus
- first stented vessel grafted into a second vessel of a recipient rodent by a method according to the invention for inserting a stent in a vessel of a rodent.
- the second vessel including the grafted first stented vessel are indicated generally by the reference numeral 1 in Fig. 1.
- the recipient rodent is a recipient mouse (not illustrated) which may be a wild mouse or may or may not be a genetically modified mouse, which may be an ApoE-KO mouse with a targeted deletion of the apolipoprotein-E gene, a mouse expressing reporter genes (LacZ, GFP, luc) an inducible mouse or a mouse expressing ere, in order to facilitate monitoring the effect of stenting in the vessel, and in particular, for monitoring the onset or otherwise of stenosis after stenting.
- the mouse if genetically modified may be otherwise genetically modified, depending on the tests or experiments to be carried out on the mouse.
- the first vessel in this embodiment of the invention is provided by a portion of a thoracic aorta 5, which has been removed from a donor mouse (not shown), which may be a wild mouse or may or may not have been genetically modified, and if genetically modified, may be similarly or differently genetically modified to the genetic modification of the recipient mouse, depending on the tests or experiments to be carried out on the recipient mouse.
- a donor mouse not shown
- the thoracic aorta 5 Prior to removal of the portion of the thoracic aorta 5, the thoracic aorta is stented, as will be described below, and is then removed from the donor mouse and grafted into the second vessel, which in this embodiment of the invention is the common carotid artery 6 of the recipient mouse.
- the thoracic aorta Prior to removal from the donor mouse, the thoracic aorta is severed from the heart. An incision is formed in the thoracic aorta adjacent the diaphragm of the donor mouse, and a stent 8, which is crimped onto a balloon 9 of a balloon catheter 10- is inserted into the thoracic aorta 5 either from the end of the thoracic aorta 5 which has been severed from the heart or through the incision.
- the balloon 9 with the stent 8 crimped thereon is located in the thoracic aorta so that the stent 8 is substantially centrally located between the severed end which has been severed from the heart, and the incision formed in the thoracic aorta 5 adjacent the diaphragm.
- This thus, leaves end portions 11 of the thoracic aorta 5 free of the stent 8 to form respective sockets 12 at the respective opposite ends of the thoracic aorta 5 for facilitating grafting of the thoracic aorta 5, when removed from the donor mouse, into the carotid artery 6 of the recipient mouse, as will be described below.
- the balloon 9 With the stent 8 centrally located in the thoracic aorta 5 by the balloon 9, the balloon 9 is inflated for expanding the stent 8 into the thoracic aorta 5.
- the stent 8 is a stainless steel slotted tubular stent of approximately 2.5mm in length, having an expanded diameter of 1.3mm to 1.5mm.
- the stent 8 in the unexpanded state is of diameter of approximately 0.5mm when crimped onto the balloon 9.
- the balloon 9 is of length of approximately 10mm and of diameter when inflated of approximately 1.25mm.
- the balloon 9 is inflated to a pressure of approximately 8 atmospheres for approximately 10 seconds for expanding the stent 8 to its expanded diameter of between 0.5 mm and 1.5mm within the thoracic aorta 5, see Fig. 4.
- the balloon 9 is deflated and removed along with the balloon catheter 10.
- the thoracic aorta 5 is severed adjacent the incision which had been formed for accommodating the balloon catheter 10, and is removed from the donor mouse for grafting into the carotid artery 6 of the recipient mouse.
- the end portions 11 which are free of the stent 8 form the respective sockets 12 at the respective opposite ends of the removed stented thoracic aorta 5 for facilitating grafting of the removed portion of the thoracic aorta 5 into the carotid artery 6, as will be described below.
- the recipient mouse is prepared for grafting of the stented thoracic aorta 5 into the carotid artery 6.
- An incision is made in the neck of the recipient mouse to expose the common carotid artery between its thoracic inlet and its bifurcation portion, and its carotid artery is clamped at the thoracic inlet and its bifurcation end to prevent blood flow there through.
- the clamping of the carotid artery 6 is not illustrated, but will be understood by those skilled in the art.
- the carotid artery 6 is then severed intermediate the clamped portions to form respective severed ends 13.
- a pair of collars 15 of polypropylene material each having an external diameter of 0.65mm and a central bore 16 extending there through are provided to form the respective severed ends 13 of the carotid artery into plug ends 17 for plugging into the corresponding sockets 12 formed in the stented thoracic aorta 5, as will be described below, see Figs. 2, 5 and 6. Initially, each severed end 13 is passed through the bore 16 of the corresponding collar 15 as illustrated in Fig.
- a portion 18 adjacent the corresponding severed end 15 is folded back over the corresponding collar 15, so that the folded portion 18 extends circumferentially around and embraces the collar 15, with the collar 15 effectively sandwiched between a portion of the carotid artery 6 extending through the bore 16 and the folded portion 18.
- the folded portion 18 adjacent each severed end 13 is secured to the corresponding collar 15 by a ligature, namely, a first suture 19 extending around the folded portion 18 and tied for securing the folded portion 18 tightly on an outer surface 20 of the collar 15 for forming the plug end 17.
- the collar 15 co-operates with the first suture 19 for retaining the folded portion 18 of the carotid artery 6 adjacent the corresponding severed end 13 securely on the collar 15.
- a tab 21 extends in a generally axial direction from each collar 15, and the folded portions adjacent the severed ends 13 are secured to the respective collars 15 with the tabs 21 extending rearwardly between the folded portions 18 of the corresponding severed ends 13 and the portions of the carotid artery 6 extending through the bore 16 for facilitating gripping of the plug end 17.
- the stented thoracic aorta 5 is located between the severed ends 13 of the carotid artery 6 of the recipient mouse, and the plug ends 17 are engaged in the sockets 12 defined by the respective opposite ends of the stented thoracic aorta 5.
- the portions 11 forming the sockets 12 of the stented thoracic aorta 5 are then sealably secured to the plug ends 17 by second ligatures, in this embodiment of the invention second sutures 25 which extend around the portions 11 of the sockets 12 and are tied.
- the clamps at the thoracic inlet and the bifurcation portion of the carotid artery 6 are released and the incision in the neck of the mouse is sutured.
- the recipient mouse is now ready to be subjected to predetermined feeding regimes, exercising regimes, and other regimes required to carry out desired tests in order to monitor the effect of stenting on the recipient mouse.
- the mouse is subjected to such regimes for a predetermined time period, and at the end of the predetermined time period the stented aorta 5 is removed from the carotid artery 6 to facilitate tests and investigations to be carried out in order to determine the effect of stenting of the stented thoracic aorta 5.
- These include, but are not limited to, imaging of stented vessels using high throughput imaging technologies such as intravascular ultrasound, optical coherence tomography, computed tomography, and optical bioilluminscence.
- a number of recipient mice are prepared with stented thoracic aortas from donor mice grafted into the common carotid arteries of the respective recipient mice. Additionally, in order that comparative tests may be carried out on the mice which have been subjected to stenting of the thoracic aorta, and mice which have been subjected to balloon angioplasty of the thoracic aorta, and also in order that comparative tests may be carried out on control mice, recipient mice having thoracic aortas which have been subjected to balloon angioplasty are prepared using the method of the invention, and control mice are also prepared using the method according to the invention.
- the thoracic aortas of donor mice are subjected to balloon angioplasty in similar manner as the manner, in which the thoracic aortas of donor mice are stented.
- the thoracic aorta of each donor mouse is severed from the heart of the mouse, and an incision is formed in the thoracic aorta adjacent the diaphragm.
- the thoracic aorta is then subjected to balloon angioplasty by inserting a balloon on a balloon catheter into the thoracic aorta either through the severed end or through the incision.
- the respective thoracic aortas are removed from the donor mice, and grafted into the recipient mice as already described with reference to Figs. 1 to 7.
- the thoracic aorta of each donor mouse is removed by severing the thoracic aorta adjacent the heart and adjacent the diaphragm.
- the removed thoracic aorta is then grafted into the common carotid artery of the respective recipient mice as already described with reference to Figs. 1 to 7.
- stented donor thoracic aortas were grafted into the common carotid arteries of a number of wild mice using the method of the invention described with reference to Figs. 1 to 7, and harvested 1 day, 7 days, 14 days or 28 days postoperatively to determine the time course of vascular injury response to stenting in rodents using this technique.
- Stented thoracic aortas were harvested and embedded into a plasticizing resin and sectioned using a diamond tip rotary blade. Although this is a technically complex method of histology, it has the advantage of allowing sectioning of the stent struts, thus maintaining exact vessel architecture.
- Neo ⁇ ntimal hyperplasia increased progressively over the 28 day time period as evidenced by measures of both neointimal thickness and neointimal area (Table 1). Neointimal thickness also increased during the 28 day period, following a similar pattern to the measurements of neointimal area (Table 1). Total medial area remained consistent through the 4 time points and a progressive increase in the neointima to media ratio over time was also observed (Table 1). Consistent with these findings, luminal area decreased between day 1 and day 28, equating to in-stent stenosis of 1.3 ⁇ 0.2, 10.8 ⁇ 1.5, 15.6 ⁇ 1.4 and 32.9 ⁇ 2.0 percent on days 1 , 3, 7 and 28 respectively (Table 1 ). Stent expansion was not different between the various time points, indicating that in-stent stenosis was the result of neointimal hyperplasia. Furthermore, injury scores were not different amongst the time intervals (Table 1 ).
- Histological analyses of stented vessels harvested at the four time points are shown in Table 2.
- the luminal surface of the stented vessel was covered with a monolayer of leucocytes (Table 2), and a thin adherent monolayer of platelets (Table 2). Small clusters of proliferating cells were identified within the media. Monocyte/ Macrophage staining was negative.
- mural thrombi surrounded the stent struts (Table 2).
- Leucocytes and platelets were present on the injured surface and lined the organizing thrombus/neointima, which also contained some macrophages and a high proportion of proliferating cells (Table 2).
- neointima (Fig. 2), which stained positively for SMC ⁇ -actin was seen.
- Masson trichrome staining revealed that a proportion of the neointima was composed of collagen and elastin (Table 2).
- Monocyte/macrophage staining increased and was predominant in the peri-strut regions (Table 2).
- the total number of proliferating cells at 14 days was similar to 7 days, yet as a proportion of the neointima markedly decreased (Table 2). Platelet staining was absent. Twenty eight days following the procedure a marked neointima was present leading to moderate in-stent stenosis.
- stented donor thoracic aortas were grafted into the common carotid arteries of a number of wild mice using the method of the invention described with reference to Figs. 1 to 7, and donor thoracic aortas which had been subjected to balloon angioplasty were grafted into the common carotid arteries of a number of other wild mice, also using the method of the invention described with reference to Figs. 1 to 7.
- Twenty- eight days later the stented thoracic aortas and the thoracic aortas which had been subjected to the balloon angioplasty were harvested and embedded into a plasticizing resin and sectioned using a diamond tip rotary blade.
- mice and wild mice were weaned onto normal rodent diet and at eighteen to twenty-two weeks some of the mice underwent stenting using the method of the invention described with reference to Figs. 1 to 7, others underwent balloon angioplasty also using the method according to the invention described with reference to Figs. 1 to 7, and the remainder of the mice had thoracic aortas from donor mice which had not been subjected to any procedures grafted into the remaining recipient mice using the method according to the invention described with reference to Figs. 1 to 7, in order to provide control mice.
- recipient ApoE-KO mice and wild mice were provided with stented thoracic aortas
- ApoE-KO mice and wild mice were produced having thoracic aortas which had been subjected to balloon angioplasty
- ApoE-KO mice and wild mice were provided which had been subjected to grafting of donor thoracic aortas which had not been subjected to any procedure to provide control mice.
- the stented thoracic aortas, the thoracic aortas which had been subjected to balloon angioplasty, and the grafted only thoracic aortas (control) were harvested four weeks later and processed for histology as already described.
- lntimal area defined as the area inside the internal elastic lamina, lumen area, vessel area, defined as the area inside the external elastic lamina and stent expansion, the area inside the stent struts.
- vessel area defined as the area inside the external elastic lamina and stent expansion, the area inside the stent struts.
- a second study was carried out in order to compare the process of stenting to balloon angioplasty or grafting only (control) in wild-type mice versus ApoE-KO mice. Stenting was carried out using the method according to the invention described with reference to Figs. 1 to 7, and balloon angioplasty was carried out also using the method according to the invention described with reference to Figs. 1 to 7. Donor thoracic aortas which were not subject to any procedure from donor mice were grafted into the common carotid arteries of recipient mice using the method according to the invention described with reference to Figs. 1 to 7 to provide the control mice.
- intimal hyperplasia was increased compared to balloon angioplasty.
- stenting greatly increased total vessel area.
- lumen area remained significantly enlarged despite intimal hyperplasia.
- the method according to the invention provides an opportunity impossible in other animal models to directly investigate the role of other key genes in re-stenosis using knockout and transgenic mice.
- Using the method according to the invention it is also possible to track endothelial cell loss and re-population using reporter genes specific to endothelial cells, and investigate the role of endothelial progenitor cells in this process, which has previously been unexplored, and it will also be possible to investigate drug eluting stents (including polymers, biologies, drugs, and materials), and although this may be done in other animal models, the method according to the invention provides the opportunity to conduct preclinical animal trials quickly (one month) as with mice with ApoE-knockout gene develop atherosclerosis in weeks compared to months required in larger animal models.
- the method according to the invention may be carried out on rats or any other rodent. It is also envisaged that other donor vessels besides the thoracic aorta may be stented and grafted into other vessels of recipient rodents besides the carotid artery.
- the advantage of stenting the thoracic aorta is that it is the largest arterial vessel in a rodent, and thus is more suitable for stenting.
- the advantage of grafting the stented vessel into the carotid artery is that the carotid artery is a relatively easily accessible vessel.
- mice which are otherwise genetically modified While the methods according to the invention have been described in conjunction with wild-type mice and genetically modified mice, namely, ApoE-KO mice, the methods according to the invention may be carried out on mice which are otherwise genetically modified. Additionally, while the stenting and balloon angioplasty has been carried out on the donor thoracic aortas while still in the donor mice, it will be readily apparent to those skilled in the art that the stenting and balloon angioplasty of the donor thoracic aorta could be carried out after removal of the thoracic aorta from the donor mice.
- the harvested thoracic aortas were embedded into a plasticizing resin and sectioned using a diamond tip rotary blade, the plastizising resin may be removed after sectioning, and this allows for immunohistochemical staining to identify specific cells, antigenic epitopes or molecules.
- Table 1 Histomorphometric characteristics of neointimal response to stenting in wild type mice (time course).
- Neointimal Thickness ⁇ m 5.6 ⁇ 1.8 31 ⁇ 8.5* 48 ⁇ 10 110 ⁇ 4.1* t
- Neointimal area mm 2 0.01 ⁇ 0.00 0.07 ⁇ 0.01* 0.10 ⁇ 0.01 0.26 ⁇ 0.01* +
- Table 2 Cellular composition of neointimal response to stenting in C57BL/6 mice (time course).
- Collagen (% neointima) 0 0 3.34 ⁇ 2.12* 12.3 ⁇ 4.62* + t denotes P ⁇ 0.01 across all time points (ANOVA). * denotes P ⁇ 0.05 compared with previous time point (Bonferroni's Multiple Comparison Test). Data represent the mean of 6- 9 animals per group.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002643414A CA2643414A1 (en) | 2006-03-10 | 2007-03-08 | A method for stenting a vessel of a rodent and for facilitating monitoring of the effect of stenting a vessel of a rodent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE20060185 | 2006-03-10 | ||
IES2006/0185 | 2006-03-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007106389A2 true WO2007106389A2 (en) | 2007-09-20 |
WO2007106389A3 WO2007106389A3 (en) | 2008-02-14 |
Family
ID=38509998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/006053 WO2007106389A2 (en) | 2006-03-10 | 2007-03-08 | A method for stenting a vessel of a rodent and for facilitating monitoring of the effect of stenting a vessel of a rodent |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA2643414A1 (en) |
WO (1) | WO2007106389A2 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5675062A (en) * | 1994-07-18 | 1997-10-07 | President And Fellows Of Harvard College | Cellular basis of transplant arteriosclerosis in mice |
US5728131A (en) * | 1995-06-12 | 1998-03-17 | Endotex Interventional Systems, Inc. | Coupling device and method of use |
US20030208258A1 (en) * | 2002-05-02 | 2003-11-06 | Tom Reilly | Vascular grafts surrounding an expanded stent for transplantation |
WO2006008484A2 (en) * | 2004-07-16 | 2006-01-26 | Cxr Biosciences Limited | Detection of cellular stress |
-
2007
- 2007-03-08 WO PCT/US2007/006053 patent/WO2007106389A2/en active Application Filing
- 2007-03-08 CA CA002643414A patent/CA2643414A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5675062A (en) * | 1994-07-18 | 1997-10-07 | President And Fellows Of Harvard College | Cellular basis of transplant arteriosclerosis in mice |
US5728131A (en) * | 1995-06-12 | 1998-03-17 | Endotex Interventional Systems, Inc. | Coupling device and method of use |
US20030208258A1 (en) * | 2002-05-02 | 2003-11-06 | Tom Reilly | Vascular grafts surrounding an expanded stent for transplantation |
WO2006008484A2 (en) * | 2004-07-16 | 2006-01-26 | Cxr Biosciences Limited | Detection of cellular stress |
Also Published As
Publication number | Publication date |
---|---|
CA2643414A1 (en) | 2007-09-20 |
WO2007106389A3 (en) | 2008-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7585320B2 (en) | Energetically-controlled delivery of biologically active material from an implanted medical device | |
US8052745B2 (en) | Endoprosthesis | |
US7922753B2 (en) | Bifurcated stent delivery system | |
US7332160B2 (en) | Medical device and method for tissue removal and repair | |
JP4903164B2 (en) | Method for incorporating drug eluting external body into medical device, and self-expanding stent including drug eluting external body | |
CN101309653B (en) | Progenitor endothelial cell capturing with drug eluting implantable medical device | |
EP2322121B1 (en) | Stent for placement in living body, and stent delivery system | |
US20070191926A1 (en) | Stent pattern for high stent retention | |
Du et al. | Design and testing of hydrophobic core/hydrophilic shell nano/micro particles for drug-eluting stent coating | |
JP2007534441A (en) | Stent delivery system | |
JP2008539245A (en) | Medical device composition containing a controlled volume of drug combination | |
JP2007522907A (en) | Rotating catheter assembly | |
CN1748653A (en) | Medicament distribution device | |
JP2011525137A (en) | Stent fabrication by tube casting process | |
CN101014300A (en) | Metallic drug-releasing medical devices and method of making same | |
CN102448407B (en) | Stent for placement in living body, and stent delivery system | |
JP2006507021A (en) | A medical device for delivering an antiproliferative composition to an anatomical site at risk of restenosis | |
JP5227326B2 (en) | Stent having a drug eluting coating | |
US20100228337A1 (en) | Mirror image stent and method of use | |
JP2010508901A5 (en) | ||
WO2007106389A2 (en) | A method for stenting a vessel of a rodent and for facilitating monitoring of the effect of stenting a vessel of a rodent | |
JP2009518123A (en) | Adhesive polymer to improve stent retention | |
US8177830B2 (en) | Rotatable catheter assembly | |
JP2019512343A (en) | Spiral ultra-shortened stent | |
US20080234808A1 (en) | Releasable Polymer on Drug Elution Stent and Method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2643414 Country of ref document: CA |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07752734 Country of ref document: EP Kind code of ref document: A2 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, EPO FORM 1205A DATED 11/11/2009 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07752734 Country of ref document: EP Kind code of ref document: A2 |